A Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03045523 |
|
Recruitment Status :
Completed
First Posted : February 7, 2017
Last Update Posted : November 21, 2017
|
Sponsor:
Galapagos NV
Information provided by (Responsible Party):
Galapagos NV
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This clinical study is a phase IIa, multi-center, randomized, double-blind, placebo-controlled, parallel group study to evaluate two doses of orally administered GLPG2222 in adult subjects with a confirmed diagnosis of CF harbouring one F508del CFTR mutation and a second gating (class III) mutation and on stable treatment with ivacaftor.
Up to 35 evaluable subjects are planned to be included in the study. Eligible subjects must be on stable treatment with physician prescribed ivacaftor (Kalydeco®) for at least 28 days at the baseline visit. They will be randomized in a 2:2:1 ratio to receive one of two active doses of GLPG2222 (150 mg q.d. or 300 mg q.d.) or placebo q.d. administered for 29 days. Subjects will be in the study for a minimum of 6 weeks and a maximum of 10 weeks, from screening until the follow-up visit.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Cystic Fibrosis | Drug: GLPG2222 150 mg q.d. Drug: GLPG2222 300 mg q.d. Drug: Placebo | Phase 2 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 37 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis Harbouring One F508del CFTR Mutation and a Second Gating (Class III) Mutation |
| Study Start Date : | January 2017 |
| Actual Primary Completion Date : | August 11, 2017 |
| Actual Study Completion Date : | August 11, 2017 |
Resource links provided by the National Library of Medicine
Genetics Home Reference related topics:
Cystic fibrosis
MedlinePlus related topics:
Cystic Fibrosis
| Arm | Intervention/treatment |
|---|---|
| Experimental: GLPG2222 Dose 1 |
Drug: GLPG2222 150 mg q.d.
GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days |
| Experimental: GLPG2222 Dose 2 |
Drug: GLPG2222 300 mg q.d.
GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days |
| Placebo Comparator: Placebo |
Drug: Placebo
Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days |
Primary Outcome Measures :
- Changes in adverse events [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of adverse events
- Changes in abnormal laboratory [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of laboratory
- Changes in abnormal vital signs, ECG or physical examination [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]To evaluate the safety and tolerability of GLPG2222 as compared to placebo in terms of vital signs, ECG or physical examination
Secondary Outcome Measures :
- Change from baseline of Sweat chloride concentration [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
- Change from baseline of FEV1 (L) and percent predicted FEV1 for age, gender and height as assessed by spirometry [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
- Change from baseline on the respiratory domain of Revised Cystic Fibrosis Questionnaire (CFQ-R) [ Time Frame: at screening and at each study visit up to day 43 which is the final FU visit ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 99 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female subject ≥ 18 years of age, on the day of signing the Informed Consent Form (ICF).
- A confirmed clinical diagnosis of CF.
- One F508del mutation on one allele in the CFTR gene, a gating (class III) mutation (one of the following: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, or S549R) on the 2nd allele in the CFTR gene (documented in the subject's medical record or CF registry).
- Weight ≥ 40 kg.
- Stable concomitant treatment for at least 4 weeks (28 days) prior to baseline (including physician prescribed ivacaftor (Kalydeco®) 150 mg b.i.d.).
- Forced expiratory volume in 1 second (FEV1) ≥ 40% of predicted normal for age, gender and height at screening (pre- or postbronchodilator).
Exclusion Criteria:
- History of clinically meaningful unstable or uncontrolled chronic disease that makes the subject unsuitable for inclusion in the study in the opinion of the investigator.
- Unstable pulmonary status or respiratory tract infection (including rhinosinusitis) requiring a change in therapy within 4 weeks of baseline.
- Need for supplemental oxygen during the day, and >2 liters per minute (LPM) while sleeping.
- History of hepatic cirrhosis with portal hypertension (e.g., signs/symptoms of splenomegaly, esophageal varices, etc).
- Abnormal liver function test at screening; defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase and/or total bilirubin (>1.5 times ULN (CTCAE Grade 2) and/or gamma-glutamyl transferase (GGT) ≥ 3x the upper limit of normal (ULN), and/or total bilirubin (>1.5 times ULN (CTCAE Grade 2).
- Estimated creatinine clearance < 60mL/min using the Cockroft-Gault formula at screening.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03045523
Locations
Show 22 study locations
Sponsors and Collaborators
Galapagos NV
Investigators
| Study Director: | Olivier Van Steen, MD, MBA | Galapagos NV |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Galapagos NV |
| ClinicalTrials.gov Identifier: | NCT03045523 |
| Other Study ID Numbers: |
GLPG2222-CL-201 |
| First Posted: | February 7, 2017 Key Record Dates |
| Last Update Posted: | November 21, 2017 |
| Last Verified: | November 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
Additional relevant MeSH terms:
|
Cystic Fibrosis Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases |